Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob S van Binnendijk

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Vaccine|July 4, 2016
Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infectionSigrid Gouma, Hinke I Ten Hulscher, Tessa M Schurink-van 't Klooster, et al.
Nature Communications|August 3, 2024
Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trialMarieke van der Heiden, Sudarshan Shetty, Elske Bijvank, et al.
Journal of Epidemiology and Community Health|November 29, 2020
Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic waveEric R A Vos, Gerco den Hartog, Rutger M Schepp, et al.
Open Forum Infectious Diseases|March 4, 2015
Mumps serum antibody levels before and after an outbreak to assess infection and immunity in vaccinated studentsSigrid Gouma, Tessa M Schurink-Van't Klooster, Hester E de Melker, et al.
Nature Communications|July 8, 2020
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessmentCorine H GeurtsvanKessel, Nisreen M A Okba, Zsofia Igloi, et al.
Human Vaccines & Immunotherapeutics|November 6, 2025
T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort studyLobke C M Hensen, Bianca M M Streng, Femke van Wijk, et al.
Blood Advances|November 26, 2025
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyureaSabine Haggenburg, Cilia R Pothast, Quincy Hofsink, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
The Lancet. Oncology|November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialSjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
Eclinicalmedicine|June 20, 2023
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyQuincy Hofsink, Sabine Haggenburg, Birgit I Lissenberg-Witte, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Vaccine|July 4, 2016
Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infectionSigrid Gouma, Hinke I Ten Hulscher, Tessa M Schurink-van 't Klooster, et al.
Nature Communications|August 3, 2024
Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trialMarieke van der Heiden, Sudarshan Shetty, Elske Bijvank, et al.
Journal of Epidemiology and Community Health|November 29, 2020
Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic waveEric R A Vos, Gerco den Hartog, Rutger M Schepp, et al.
Open Forum Infectious Diseases|March 4, 2015
Mumps serum antibody levels before and after an outbreak to assess infection and immunity in vaccinated studentsSigrid Gouma, Tessa M Schurink-Van't Klooster, Hester E de Melker, et al.
Nature Communications|July 8, 2020
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessmentCorine H GeurtsvanKessel, Nisreen M A Okba, Zsofia Igloi, et al.
Human Vaccines & Immunotherapeutics|November 6, 2025
T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort studyLobke C M Hensen, Bianca M M Streng, Femke van Wijk, et al.
Blood Advances|November 26, 2025
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyureaSabine Haggenburg, Cilia R Pothast, Quincy Hofsink, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
The Lancet. Oncology|November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialSjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
Eclinicalmedicine|June 20, 2023
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyQuincy Hofsink, Sabine Haggenburg, Birgit I Lissenberg-Witte, et al.
Pageof 4